The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Inclusion Criteria: 1. 4 years to 70 years, expected survival \> 3 months 2. CD19 positive B-cell acute lymphoblastic leukemia 3. Karnofsky Performance Status (KPS) \>70 4. Relapsed after allogeneic or autologous stem cell transplantation (SCT); 5. Cardiac function: 1-2 levels; Liver: TBIL≤3 Upper Limit of Normal (ULN)，aspartate aminotransferase (AST) ≤2.5 ULN，ALT ≤2.5 ULN; kidney: Cr≤1.25 ULN; bone marrow: White Blood Cell (WBC) ≥ 3.0×109/L, Hb ≥90 g/L, Platelet (PLT) ≥ 80×109/L） 6. No serious allergic constitution 7. No other serous diseases that conflicts with the clinical program 8. No other cancer history 9. No serious mental disorder 10. Informed consent is signed by a subject or his lineal relation. Exclusion Criteria: 1. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test) 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive 3. Active hepatitis B or hepatitis C infection 4. Recent or current use of glucocorticoid or other immunosuppressor 5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases 6. Transaminase \>2.5 ULN, Bilirubin \>3 ULN，Creatinine\>1.25 ULN 7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products 8. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results